| Heading: |
Voluntary Scheme for Branded Medicines Pricing, Access and Growth |
| Question ID: |
1792188 |
| UIN: |
43867 |
| House: |
Commons |
| Date tabled: |
2025-04-03 |
| Asking Member ID: |
4124 |
| Asking Member display name: |
Chi Onwurah
|
| Asking Member handle: |
ChiOnwurah
|
| Asking Member Twitter reference: |
@ChiOnwurah
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the repayment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth on the UK life sciences sec |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-04-09 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4981 |
| Answering Member display name: |
Ashley Dalton
|
| Answering Member handle: |
AshleyDalton_MP
|
| Answering Member Twitter reference: |
@AshleyDalton_MP
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The voluntary scheme for branded medicines pricing, access, and growth (VPAG) is a unique partnership between the Government and the pharmaceutical industry and includes a range of commitments to support innovation and improve National Health Service acce... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |